EN DE
Watch Guangzhou Innogen Pharm Grp Co for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Guangzhou Innogen Pharm Grp Co (2591) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Guangzhou Innogen Pharm Grp Co stock HK$3.15, price HK$3.55, that is 11.3% below the price, quality 33 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

GI Guangzhou Innogen Pharm Grp Co logo Thin data Nov 10, 2026

Guangzhou Innogen Pharm Grp Co

2591 · HK

Expensive (fair value 11% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Revenue last quarter +39% vs. a year ago. 
Mixed vs. peers (4/8) 
Fair value HK$3.15 · Overvalued 
Quality 33/100 
Falling price (downtrend) 
Weak Growth 
Negative free cash flow 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch Guangzhou Innogen Pharm Grp Co for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$57.25 HK$3.09 Fair Value HK$3.15 Aug 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

15‑month range HK$3.09 – HK$57.25 · fair‑value band HK$2.36 – HK$3.94 · the HK$3.55 price screens above the HK$3.15 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Guangzhou Innogen Pharm Grp Co in your weekly email

Every Wednesday you see whether Guangzhou Innogen Pharm Grp Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Guangzhou Innogen Pharmaceutical Group Co., Ltd engages in the development of drug engaged in the research, development and commercialization of pharmaceutical products.

Show moreShow less

The company's products are used for the treatment of metabolic diseases, including diabetes, obesity and overweight, and MASH; and other major central nervous system diseases. The company was incorporated in 2014 and is based in Shanghai, China.

Stock analysis

Guangzhou Innogen Pharm Grp Co (2591) currently trades at HK$3.55, while our estimate is HK$3.15, 11% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$2.36 (bear) to HK$3.94 (bull), the price of HK$3.55 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Guangzhou Innogen Pharm Grp Co reported revenue of 128M CNY in FY2025 versus 0 CNY in FY2023. Reported net income was −333M CNY in FY2025.

Key figures

Market cap HK$1.6B (≈ $207M) Micro · P/S ratio 9.58 · Return on equity −41.2% · Return on assets (EBIT) −39.5% (4-year average) · Operating margin −153% · Revenue (TTM) 153M CNY · Revenue growth (YoY) +38.6% · Free cash flow −318M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 92% below its 52-week high and 15% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −11%, 2591 screens richer than that median.

Fair Value

Bear HK$2.36 Fair Value HK$3.15 Bull HK$3.94
Price HK$3.55 · Downside -11.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 58
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 73
Debt, balance sheet and risk of trouble
Investment 5
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 56
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

2591 screens overvalued: fair value 11% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Guangzhou Innogen Pharm Grp Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 33 · Below median
Fair Value upside −11.3% · Above median
Profitability
Return on assets −21.2% · Above median
Operating margin (12 months) −153.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 38.6% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.31× · Cheapest 25%
P/S (12 months) 9.00× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)18 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs 2591
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs 2591
Samsung Biologics Co 207940 1,411,000 KRW 1,552,100 KRW +10% vs 2591
Genmab A/S GMAB kr 3,448 kr 3,793 +10% vs 2591
argenx SE ARGX $960.04 $908.40 −5% vs 2591
CSL Limited CSL A$202.52 A$185.51 −8% vs 2591
Moderna, Inc MRNA $223.37 $139.99 −37% vs 2591
Revolution Medicines, Inc RVMD $172.29 $88.78 −48% vs 2591
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs 2591
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs 2591

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Guangzhou Innogen Pharm Grp Co: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Guangzhou Innogen Pharm Grp Co Fair Value". https://www.fairvalue-calculator.com/stock/2591

Frequently asked questions

Is Guangzhou Innogen Pharm Grp Co (2591) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$3.15 versus a price of HK$3.55, about 11% lower (overvalued).
What is the fair value of 2591?
Our estimate for Guangzhou Innogen Pharm Grp Co is HK$3.15 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$3.55.
What is the quality score of 2591?
Guangzhou Innogen Pharm Grp Co has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Guangzhou Innogen Pharm Grp Co (2591)?
Our calculated price target is the estimate of HK$3.15 (as of Nov 10, 2026). Cautious scenario HK$2.36, optimistic scenario HK$3.94. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Guangzhou Innogen Pharm Grp Co stock forecast for 2026?
Our estimate puts fair value at HK$3.15, about 11% lower versus a price of HK$3.55 (overvalued). Cautious scenario HK$2.36, optimistic scenario HK$3.94. The calculation is refreshed regularly with new filings.
What is the revenue of Guangzhou Innogen Pharm Grp Co (2591)?
Guangzhou Innogen Pharm Grp Co reported trailing-twelve-month revenue of about 153M CNY (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Guangzhou Innogen Pharm Grp Co (2591)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Guangzhou Innogen Pharm Grp Co it is HK$3.15 per share (as of Nov 10, 2026), against a price of HK$3.55.
Is Guangzhou Innogen Pharm Grp Co stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 2591 trades above its calculated fair value: price HK$3.55, fair value HK$3.15, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2591?
No. The price is what the market pays today (HK$3.55); the fair value is what the company's own numbers justify (HK$3.15). For Guangzhou Innogen Pharm Grp Co the two are HK$0.4000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Guangzhou Innogen Pharm Grp Co worth?
The market values Guangzhou Innogen Pharm Grp Co at about HK$1.6B (market capitalisation, as of Nov 10, 2026). Per share that is HK$3.55; our models calculate a fair value of HK$3.15 per share.
What do the bullish and bearish scenarios say about 2591?
Our models span a range for Guangzhou Innogen Pharm Grp Co: cautious scenario HK$2.36, base HK$3.15, optimistic HK$3.94 per share (as of Nov 10, 2026, price HK$3.55). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Guangzhou Innogen Pharm Grp Co (2591)?
Balance-sheet figures for Guangzhou Innogen Pharm Grp Co (as of Nov 10, 2026): return on equity −41.2%. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is 2591 from its 52-week high?
Guangzhou Innogen Pharm Grp Co trades at HK$3.55, about 92% below its 52-week high of HK$44.00 and 15% above the low of HK$3.09 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$3.15 is for.
Which stocks are comparable to Guangzhou Innogen Pharm Grp Co?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Guangzhou Innogen Pharm Grp Co stock attractive at the current price?
The data as of Nov 10, 2026: price HK$3.55, calculated fair value HK$3.15 (−11%), Quality Score 33/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Guangzhou Innogen Pharm Grp Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Guangzhou Innogen Pharm Grp Co (2591)?
The closing price on Nov 13, 2026 was HK$3.55. Our estimate is HK$3.15, about 11% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Guangzhou Innogen Pharm Grp Co right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Guangzhou Innogen Pharm Grp Co

How large is the market capitalisation of Guangzhou Innogen Pharm Grp Co (2591)?
The market capitalisation of Guangzhou Innogen Pharm Grp Co is HK$1.6B (≈ $207M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Guangzhou Innogen Pharm Grp Co (2591)?
The price-to-sales ratio of Guangzhou Innogen Pharm Grp Co is 9.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Guangzhou Innogen Pharm Grp Co (2591)?
The return on equity (ROE) of Guangzhou Innogen Pharm Grp Co is −41.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Guangzhou Innogen Pharm Grp Co (2591)?
On an EBIT basis the return on assets of Guangzhou Innogen Pharm Grp Co is −39.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Guangzhou Innogen Pharm Grp Co (2591)?
The operating margin of Guangzhou Innogen Pharm Grp Co is −153% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Guangzhou Innogen Pharm Grp Co (2591)?
Revenue at Guangzhou Innogen Pharm Grp Co is growing 38.6% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Guangzhou Innogen Pharm Grp Co (2591) generate?
The free cash flow of Guangzhou Innogen Pharm Grp Co is −318M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Guangzhou Innogen Pharm Grp Co (2591) hold?
Guangzhou Innogen Pharm Grp Co holds more cash than debt, 803M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Guangzhou Innogen Pharm Grp Co in the live analysis

One click puts Guangzhou Innogen Pharm Grp Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.